Published in Biochem J on November 01, 1993
Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J (1999) 2.40
Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell line. Immunology (1994) 0.92
Characterization of Neospora caninum surface protein NcSRS2 based on baculovirus expression system and its application for serodiagnosis of Neospora infection. J Clin Microbiol (2001) 0.91
Expression of rat CD59: functional analysis confirms lack of species selectivity and reveals that glycosylation is not required for function. Immunology (1997) 0.88
Glycosylphosphatidylinositol anchor-dependent stimulation pathway required for generation of baculovirus-derived recombinant scrapie prion protein. J Virol (2011) 0.85
Expression of a glycosylphosphatidylinositol-anchored Trypanosoma brucei transferrin-binding protein complex in insect cells. Proc Natl Acad Sci U S A (1994) 0.85
Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack. Immunology (1995) 0.85
Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science (1981) 23.67
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol (1990) 2.48
Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 2.01
Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem (1988) 2.00
A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol (1989) 1.98
Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. Mol Immunol (1989) 1.94
Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59. Science (1992) 1.68
CD59 functions as a signal-transducing molecule for human T cell activation. J Immunol (1991) 1.56
Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J (1992) 1.43
20 KDa homologous restriction factor of complement resembles T cell activating protein. Biochem Biophys Res Commun (1989) 1.31
Oligosaccharide processing in the expression of human plasminogen cDNA by lepidopteran insect (Spodoptera frugiperda) cells. Biochemistry (1990) 1.22
Association of the CD59 and CD55 cell surface glycoproteins with other membrane molecules. J Immunol (1991) 1.14
CD58 and CD59 molecules exhibit potentializing effects in T cell adhesion and activation. J Immunol (1992) 1.09
Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity. J Biol Chem (1992) 1.07
Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. J Biol Chem (1991) 1.05
Structural properties of the glycoplasmanylinositol anchor phospholipid of the complement membrane attack complex inhibitor CD59. Clin Exp Immunol (1992) 0.99
The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity. Immunology (1993) 0.99
The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility. Eur J Immunol (1990) 0.94
Structures of the asparagine-289-linked oligosaccharides assembled on recombinant human plasminogen expressed in a Mamestra brassicae cell line (IZD-MBO503). Biochemistry (1991) 0.93
Dual function of recombinant human CD58: inhibition of T cell adhesion and activation via the CD2 pathway. Int Immunol (1991) 0.88
Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement. Eur J Immunol (1991) 0.87
Species-specific restriction of complement by HRF20 (CD59) generated by cDNA transfection. Eur J Immunol (1992) 0.83
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Immunoaffinity purification of human complement component C9 using monoclonal antibodies. J Immunol Methods (1983) 2.11
Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol (1987) 1.92
Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59. Biochemistry (1994) 1.84
Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood (2001) 1.65
Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. J Exp Med (1997) 1.65
The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol (1993) 1.59
Monoclonal antibodies demonstrate protection of polymorphonuclear leukocytes against complement attack. Nature (1985) 1.59
Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol (2001) 1.58
Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology (2000) 1.56
Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature (1989) 1.49
The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem J (1985) 1.49
Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med (2000) 1.48
Role and regulation of pig CD59 and membrane cofactor protein/CD46 expressed on pig aortic endothelial cells. Transplantation (2000) 1.43
Isolation and characterization of a membrane protein from rat erythrocytes which inhibits lysis by the membrane attack complex of rat complement. Biochem J (1992) 1.43
A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry (1987) 1.42
Perforin is activated by a proteolytic cleavage during biosynthesis which reveals a phospholipid-binding C2 domain. EMBO J (1997) 1.42
The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J (1988) 1.41
Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol (1997) 1.41
Exogenous glycosyl phosphatidylinositol-anchored CD59 associates with kinases in membrane clusters on U937 cells and becomes Ca(2+)-signaling competent. J Cell Biol (1995) 1.40
Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol (1995) 1.35
Inhibition of complement-induced [14C]sucrose release by intracellular and extracellular monoclonal antibodies to C9: evidence that C9 is a transmembrane protein. Biochem Biophys Res Commun (1984) 1.33
Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol (1999) 1.32
Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol (1994) 1.30
Tissue distribution of complement regulatory membrane proteins in rats. Immunology (1994) 1.29
The glycosylation of the complement regulatory protein, human erythrocyte CD59. J Biol Chem (1997) 1.28
Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol (2000) 1.27
Human factor H-related protein 5 (FHR-5). A new complement-associated protein. J Biol Chem (2000) 1.26
Intracellular Ca2+ and cell injury: a paradoxical role of Ca2+ in complement membrane attack. Cell Calcium (1986) 1.25
Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium. Am J Pathol (1994) 1.24
Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol (1991) 1.22
The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol (1998) 1.22
Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol (1996) 1.21
Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. J Neuroimmunol (1989) 1.20
Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology (2000) 1.19
Complement regulation at the molecular level: the structure of decay-accelerating factor. Proc Natl Acad Sci U S A (2004) 1.17
Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clin Exp Immunol (2008) 1.17
Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology (1992) 1.17
Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol (1995) 1.14
Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Complement activation and attack in the absence of anti-myelin antibodies. J Neurol Sci (1989) 1.13
The role of complement in the pathogenesis of experimental allergic encephalomyelitis. Brain (1989) 1.13
Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack. Immunology (1990) 1.12
Induction of decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood (1999) 1.10
Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J Clin Invest (1995) 1.10
Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J Immunol Methods (1999) 1.09
Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis Rheum (2004) 1.09
Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clin Exp Immunol (2009) 1.09
Immunoradiometric assay for human complement component C9 utilising monoclonal antibodies. Clin Chim Acta (1983) 1.08
Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol (1997) 1.08
Sphingomyelinases in the venom of the spider Loxosceles intermedia are responsible for both dermonecrosis and complement-dependent hemolysis. Biochem Biophys Res Commun (1998) 1.08
Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem J (1999) 1.07
Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol (1999) 1.07
Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J Clin Lab Immunol (1992) 1.07
In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J Exp Med (1994) 1.06
Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet (1992) 1.06
Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol (1989) 1.05
Reversible cell damage by T-cell perforins. Calcium influx and propidium iodide uptake into K562 cells in the absence of lysis. Biochem J (1990) 1.05
Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: functional relevance and role in inflammation. Immunology (1995) 1.05
Complement mediated cell death is associated with DNA fragmentation. Cell Death Differ (2000) 1.05
Complement-inhibiting activities of human CD59 and analogues from rat, sheep, and pig are not homologously restricted. J Immunol (1994) 1.04
Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye (Lond) (2011) 1.04
Molecular cloning of the rat analogue of human CD59: structural comparison with human CD59 and identification of a putative active site. Biochem J (1994) 1.03
Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency. Immunology (1992) 1.03
Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology (1992) 1.02
Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55). J Immunol (1998) 1.02
Identification and characterization of complement C3 receptors on human astrocytes. J Immunol (1996) 1.01
Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clin Exp Immunol (2000) 1.01
Tissue distribution of the rat analogue of decay-accelerating factor. Immunology (1999) 1.01
Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest (1999) 0.99
Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation. Clin Exp Immunol (1991) 0.99
The sheep analogue of human CD59: purification and characterization of its complement inhibitory activity. Immunology (1993) 0.99
Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage. Immunology (1984) 0.99
Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol (1995) 0.98
The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells. Clin Exp Immunol (1991) 0.98
Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet (1984) 0.98
2-Chloroadenosine inhibits complement-induced reactive oxygen metabolite production and recovery of human polymorphonuclear leucocytes attacked by complement. Biochem Biophys Res Commun (1985) 0.97
Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol (1989) 0.97
Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol (2002) 0.97
Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat. Arthritis Rheum (2000) 0.97
CD59 protects glomerular endothelial cells from immune-mediated thrombotic microangiopathy in rats. J Am Soc Nephrol (1998) 0.97
Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF. J Infect Dis (2000) 0.96
Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis. J Immunol (1986) 0.96
Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol (1994) 0.96
Terminal complement complexes and C1/C1 inhibitor complexes in autoimmune thyroid disease. Clin Exp Immunol (1989) 0.96
Molecular bases of combined subtotal deficiencies of C6 and C7: their effects in combination with other C6 and C7 deficiencies. J Immunol (1996) 0.96
Complement activation and inhibition in experimental models of arthritis. Mol Immunol (2000) 0.95
Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J Immunol (1995) 0.95
Reversible injury of cultured rat oligodendrocytes by complement. Immunology (1989) 0.95
The ninth complement component in rheumatoid arthritis, Behçet's disease and other rheumatic diseases. Br J Rheumatol (1986) 0.95
Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. Eur J Immunol (1996) 0.94
Role of complement in the aetiology of Pick's disease? J Neuropathol Exp Neurol (1996) 0.94
Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis. Clin Exp Immunol (1997) 0.93
Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int (1995) 0.93
Presence of a dysfunctional form of CD59 on a CD59+ subclone of the U937 cell line. Immunology (1994) 0.92
Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol (1996) 0.92
Human protectin (CD59), an 18-20-kD homologous complement restriction factor, does not restrict perforin-mediated lysis. J Exp Med (1990) 0.91
Development of a model for cytomegalovirus infection of oligodendrocytes. J Gen Virol (1997) 0.91